

# 2010 Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement

RAGNAR HANAS, MD, PHD<sup>1</sup>

GARRY JOHN, FRCPATH<sup>2</sup>

ON BEHALF OF THE INTERNATIONAL HbA<sub>1c</sub>

CONSENSUS COMMITTEE\*

**G**lycated hemoglobin concentrations (most commonly hemoglobin A1C; HbA<sub>1c</sub>) reflect time-averaged blood glucose during the previous 2–3 months and are used as the gold standard for long-term follow-up of glycemic control. Standardization with common calibration was first proposed in 1984 (1). It was only after the publication of the Diabetes Control and Complications Trial (DCCT) study in 1993 (2), however, that the issue of international standardization of HbA<sub>1c</sub> measurements became an important objective for scientists and clinicians. At that time, the lack of international standardization resulted in several countries developing National standardization programs; most notable of these are:

- in the U.S., the National Glycohemoglobin Standardization Program (NGSP), with the DCCT HPLC method used as the primary reference method;
- in Sweden, with the Mono S ion exchange chromatography designated as the comparison method;
- in Japan, with use of common calibrators (six calibrators available for use) with HbA<sub>1c</sub> values assigned by the Japan Diabetes Society.

A common feature of these national programs is the absence of primary and secondary reference materials. To overcome this lack of reference materials, achieve

global standardization, and meet the requirements of the European Union directive on in vitro diagnostic (IVD) medical devices, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) established a Working Group on HbA<sub>1c</sub> Standardization to develop a reference measurement system within the concept of metrological traceability. Such a system has been developed consisting of incubation with the enzyme endoproteinase Glu-C, cleavage of the NH<sub>2</sub>-terminal hexapeptide of the  $\beta$ -chain, and separation and quantification of glycated and nonglycated hexapeptides by mass spectrometry or capillary electrophoresis (3). The analyte measured is a hemoglobin molecule having a stable adduct of glucose to the NH<sub>2</sub>-terminal valine of the hemoglobin  $\beta$ -chain ( $\beta$ N-1-deoxyfructosyl-hemoglobin). Pure HbA<sub>1c</sub> and pure HbA<sub>0</sub> are isolated from human blood and mixed in well-defined proportions to produce a certified primary reference material set used to calibrate the primary reference measurement system (PRMS). The PRMS values are assigned to secondary reference materials (SRMs; whole blood), and the SRMs are used by the manufacturers to calibrate their instruments. A laboratory network has been established to implement and maintain the PRMS (4).

Adopting the new IFCC standardization procedure will result in HbA<sub>1c</sub> percentage values being lowered due to the

higher specificity on the reference method. It has been suggested that lowering the percentage value of the HbA<sub>1c</sub> reported may lead to poorer glycemic control in some patients (5), and IFCC has recommended the use of SI (Système International) units of mmol/mol, which would minimize the risk of confusion between IFCC percentage units and DCCT/NGSP percentage units (6).

Expressing HbA<sub>1c</sub> as an average glucose concentration has been widely discussed, as there is a convincing linear relationship between HbA<sub>1c</sub> and average glucose concentration in both adults (7) and children (8). Nevertheless, not all population groups have been evaluated adequately.

Clinicians and scientists have unanimously welcomed the use of the IFCC reference method for calibration purposes, and the implementation of this standardization process is ongoing. There has been a considerable debate, however, regarding the number issue, i.e., whether HbA<sub>1c</sub> should be expressed in percentage units related to the DCCT study or mmol/mol related to the IFCC method. There is an evident need to keep doctors, nurses, and people with diabetes educated to ensure a worldwide understanding of previously reported and upcoming scientific HbA<sub>1c</sub> results. A first consensus meeting was held in 2007 (9–10), where it was decided that the new IFCC reference system for HbA<sub>1c</sub> represents the only valid anchor to implement standardization of the measurement, and that HbA<sub>1c</sub> results were to be reported worldwide in IFCC units (mmol/mol) and derived NGSP units (%), using the IFCC-NGSP master equation.

A second consensus meeting was held at the International Diabetes Federation (IDF) meeting in Montreal on 21 October 2009. The American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), the IDF, the IFCC, and the International Society for Pediatric and Adolescent Diabetes (ISPAD) were represented at that meeting, as well as some editors from medical journals, and the following statements were approved by these organizations:

From the <sup>1</sup>Department of Pediatrics, Uddevalla Hospital, Uddevalla, Sweden; and the <sup>2</sup>Department of Laboratory Medicine, Norfolk and Norwich University Hospital Norwich, Norfolk, U.K.

Corresponding author: Ragnar Hanas, ragnar.hanas@vgregion.se.

\*A complete list of the members of the International HbA<sub>1c</sub> Consensus Committee can be found in the APPENDIX.

This article is being simultaneously published in 2010 in *Annals of Clinical Biochemistry*, *Clinical Chemistry*, *Clinical Chemistry and Laboratory Medicine*, *Diabetes Care*, *Diabetes Research and Clinical Practice*, *Diabetologia*, *Diabetic Medicine*, and *Pediatric Diabetes*.

DOI: 10.2337/dc10-0953

©2010 by the American Diabetes Association, the European Association for the Study of Diabetes, the International Diabetes Federation, the International Federation of Clinical Chemistry and Laboratory Medicine, and the International Society for Pediatric and Adolescent Diabetes. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

1. HbA<sub>1c</sub> test results should be standardized worldwide, including the reference system and results reporting.
2. The IFCC reference system for HbA<sub>1c</sub> represents the only valid anchor to implement standardization of the measurement.
3. HbA<sub>1c</sub> results are to be reported by clinical laboratories worldwide in SI (Système International) units (mmol/mol, no decimals) and derived NGSP units (% , one decimal), using the IFCC-NGSP master equation (DCCT units).
4. HbA<sub>1c</sub> conversion tables including both SI (IFCC) and NGSP/DCCT units should be easily accessible to the diabetes community.
5. Editors of journals and other printed material are strongly recommended to require that submitted manuscripts report HbA<sub>1c</sub> in both SI (IFCC) and NGSP/DCCT units.
6. The reportable term for glycated hemoglobin is HbA<sub>1c</sub>, although other abbreviations may be used in guidelines and educational material (A1C).
7. The above consensus recommendations apply through 2011, when they will be discussed again at the next consensus meeting at the IDF meeting in Dubai, December 2011.

HbA<sub>1c</sub>-derived average glucose values (ADAGs) calculated from the HbA<sub>1c</sub> results were not included in the consensus due to the above-mentioned limitations of this procedure. However, the use of an estimated average glucose (eAG) (7) in discussion with an individual patient may add to the consultation process, and the availability of such estimation may be advantageous. Agreement should be reached at a local level on how to make this estimation available.

In a world of increased communication, and with the ever-increasing availability of information that both lay people and professionals may access via the Internet, it is inevitable that scientific results from studies such as the DCCT will be brought to the attention of interested individuals for decades to come. By report-

ing in both IFCC and DCCT units, ongoing continuity between these reporting systems will be ensured. The submission of manuscripts containing both units will facilitate the alignment of the various HbA<sub>1c</sub> methods, as the master equation will be used in the laboratory instruments for calculating the DCCT units, i.e., both the IFCC units and the DCCT units will have the same basis. It is therefore of vital importance that all laboratories and other users of instruments for measuring HbA<sub>1c</sub>, either in the laboratory or at the point of care, take part in quality control and quality assessment programs to ensure accurate results (individual countries will vary in the way this is performed). We hope that the recommendation of dual reporting in submitted manuscripts will be adopted promptly by all scientific journals publishing diabetes articles.

## APPENDIX

### International HbA<sub>1c</sub> Consensus Committee members

For ADA: David Kendall, Sue Kirkman, Sue McLaughlin, Richard Bergenstal, David Sacks, and David Nathan. For EASD: Viktor Joergens and Ulf Smith. For IDF: Jean-Claude Mbanya, Massimo Massi Benedetti, Marg McGill, and Larry Deeb. For IFCC: Garry John and Graham Beastall. For ISPAD: Ragnar Hanas and Thomas Danne.

**Acknowledgments**—No potential conflicts of interest relevant to this article were reported.

### References

1. Peterson CM, Jovanovic L, Raskin P, Goldstein DE. A comparative evaluation of glycosylated haemoglobin assays: feasibility of references and standards. *Diabetologia* 1984;26:214–217
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med* 1993;329:977–986

3. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM, IFCC Working Group on HbA<sub>1c</sub> Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. *Clin Chem* 2004;50:166–174
4. Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jeppsson JO, Goodall I, Miedema K, Myers G, Reinauer H, Sacks DB, Slingerland R, Siebelder C. The IFCC Reference Measurement System for HbA<sub>1c</sub>: a 6-year progress report. *Clin Chem* 2008;54:240–248
5. Hanas R. Psychological impact of changing the scale of reported HbA(1c) results affects metabolic control. *Diabetes Care* 2002;25:2110–2111
6. International Federation Of Clinical Chemistry And Laboratory Medicine, IFCC Scientific Division, Nordin G, Dybkaer R. Recommendation for term and measurement unit for “HbA1c”. *Clin Chem Lab Med* 2007;45:1081–1082
7. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008;31:1473–1478
8. Diabetes Research in Children Network (DirecNet) Study Group. Relationship of A1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glucose determinations by sensors. *Diabetes Care* 2008;31:381–385
9. American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. *Diabetes Care* 2007;30:2399–2400
10. American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA1c measurement. *Diabetologia* 2007;50:2042–2043